Efficacy and safety of nab-paclitaxel plus gemcitabine in the treatment of advanced pancreatic cancer by transcatheter arterial chemotherapy: a retrospective study

宁周雨; 花永强; 徐立涛; 庄丽萍; 冯兰云; 陈　颢; 王　鹏; 沈晔华; 林钧华; 陈　震; 孟志强

doi:10.19401/j.cnki.1007-3639.2020.02.007

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of nab-paclitaxel plus gemcitabine in the treatment of advanced pancreatic cancer by transcatheter arterial chemotherapy: a retrospective study

更新时间：2026-01-27

- Efficacy and safety of nab-paclitaxel plus gemcitabine in the treatment of advanced pancreatic cancer by transcatheter arterial chemotherapy: a retrospective study
- China Oncology Vol. 30, Issue 2, Pages: 128-134(2020)
- 作者机构：
  
  复旦大学附属肿瘤医院肿瘤微创治疗中心，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2020.02.007
  CLC： R735.9
- Published Online：06 March 2020，
  
  Published：06 March 2020
- 稿件说明：
移动端阅览
宁周雨, 花永强, 徐立涛, 庄丽萍, 冯兰云, 陈　颢, 王　鹏, 沈晔华, 林钧华, 陈　震, 孟志强. 白蛋白结合型紫杉醇联合吉西他滨动脉灌注治疗进展期胰腺癌的安全性和有效性回顾性研究[J]. 中国癌症杂志, 2020, 30(2): 128-134.

宁周雨, 花永强, 徐立涛, et al. Efficacy and safety of nab-paclitaxel plus gemcitabine in the treatment of advanced pancreatic cancer by transcatheter arterial chemotherapy: a retrospective study[J]. China Oncology, 2020, 30(2): 128-134.
宁周雨, 花永强, 徐立涛, 庄丽萍, 冯兰云, 陈　颢, 王　鹏, 沈晔华, 林钧华, 陈　震, 孟志强. 白蛋白结合型紫杉醇联合吉西他滨动脉灌注治疗进展期胰腺癌的安全性和有效性回顾性研究[J]. 中国癌症杂志, 2020, 30(2): 128-134. DOI： 10.19401/j.cnki.1007-3639.2020.02.007.

宁周雨, 花永强, 徐立涛, et al. Efficacy and safety of nab-paclitaxel plus gemcitabine in the treatment of advanced pancreatic cancer by transcatheter arterial chemotherapy: a retrospective study[J]. China Oncology, 2020, 30(2): 128-134. DOI： 10.19401/j.cnki.1007-3639.2020.02.007.

摘要

背景与目的：白蛋白结合型紫杉醇联合吉西他滨（nab-paclitaxel combined with gemcitabine，AG）方案静脉化疗是进展期胰腺癌有效治疗方案之一，动脉灌注化疗（transcatheter arterial chemotherapy，TAC）具有增强疗效并降低不良反应的优势，观察AG方案经TAC治疗进展期胰腺癌患者的有效性和安全性。方法：回顾性分析2016年1月—2019年6月复旦大学附属肿瘤医院收治的63例接受治疗的进展期胰腺癌患者，患者均经病理学检查确诊为胰腺导管腺癌，其中Ⅲ期15例，Ⅳ期48例，所有患者接受经动脉灌注化疗和（或）栓塞治疗，动脉灌注化疗用药方案为盐酸吉西他滨1 000 mg/m

联合白蛋白结合型紫杉醇125 mg/m

，灌注时间≥10 min，伴有肝转移者同时行供血动脉栓塞。结果：63例患者中，术中行数字减影血管造影（digital subtraction angiography，DSA）可见胰腺肿瘤和肝转移灶动脉供血比例分别为66.67%和35.29%；接受治疗1次4例，2次6例，3次6例，4次及以上47例，治疗次数最多为9次，间隔时间为21～45 d。1年生存率为36.51%，中位生存期（median overall survival，mOS）为9.2个月，6个月无进展生存（progression-free survival，PFS）率为44.44%，中位PFS（median PFS，mPFS）为4.7个月。多因素分析显示KPS≥80、Ⅲ期与较长的生存期相关，接受多次动脉灌注化疗和（或）栓塞是良好的生存预后相关因素。发生治疗相关的Ⅲ度及以上血液学不良反应包括中性粒细胞减少（3.17%）和血小板下降（4.76%），非血液学不良反应包括乏力（6.35%）、恶心呕吐（9.52%）、腹泻（4.76%）和转氨酶升高（4.76%）；17.46%和22.22%的患者出现发热及肝区疼痛栓塞综合征，所有不良反应经治疗后均好转，无治疗相关性死亡病例。结论：白蛋白结合型紫杉醇联合吉西他滨经动脉灌注治疗进展期胰腺癌具有较好的安全性，不良反应与静脉给药相比有所减少，可有效地控制病情，使患者生存获益。

Abstract

Background and purpose: Intravenous chemotherapy of nab-paclitaxel combined with gemcitabine (AG) is one of the effective treatment options for advanced pancreatic cancer

and transcatheter arterial chemotherapy (TAC) has the advantage of enhancing efficacy and reducing side effects. This study aimed to evaluate the efficacy and safety of AG regimen in the treatment of advanced pancreatic cancer by transcatheter arterial chemotherapy/chemoembolization (TAC/TACE). Methods: We retrospectively analyzed 63 advanced pancreatic cancer patients who were treated at Fudan University Shanghai Cancer Center from Jan. 2016 to Jun. 2019. All patients received arterial infusion chemotherapy and/or embolization

and the TAC regimen consisted of nab-paclitaxel 125 mg/m

combined with gemcitabine hydrochloride 1 000 mg/m

perfusion ≥10 minutes. If accompanied by liver metastasis

embolization was implemented. Results: Among 63 patients

the arterial blood supply ratios of pancreatic tumors and liver metastases in digital subtraction angiography (DSA) were 66.67% and 35.29% respectively. Four patients received treatment once

6 patients received treatment twice

6 patients received treatment 3 times

and 47 patients received treatment 4 times or more. The maximum number of treatment was 9 times

with an interval of 21-45 d. The 1-year overall survival (OS) rate was 36.51%. Median OS (mOS) was 9.2 months. The 6-month progression-free survival (PFS) rate was 44.44%

and the median PFS (mPFS) was 4.7 months. Multivariate analysis showed that KPS≥80 and stage Ⅲ were associated with longer survival

and multiple TAC/TACE treatment was suggested as good prognostic factor. Conclusion: AG has better safety in the treatment of pancreatic cancer by transarterial infusion chemotherapy. Compared with intravenous chemotherapy

AG can reduce the adverse reactions

effectively control the disease and prolong patients' survival.

关键词

Keywords

references

Views

3693

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Retrospective analysis of adjuvant therapy with dabrafenib and trametinib for 24 patients with malignant melanoma

Liposomal paclitaxel in combination with cisplatin as a first line of chemotherapy in treatment of advanced NSCLC with regional lymph node metastasis: A randomized controlled trial

A research on the mechanism of SERPINA3 promoting malignant progression and gemcitabine resistance of pancreatic cancer by inhibiting ferroptosis

Expert consensus on the combination of anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma (2025 edition)

Effect of liposome binding antisense oligonucleotide BP1003 on albumin-bound paclitaxel sensitivity in pancreatic cancer cells by inhibiting STAT3

Related Author

Dongdong JIA

Tao LI

罗虎

杨静翔

宫亮

陈永峰

唐春兰

杨和平

Related Institution

Department of Bone and Soft-tissue Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences

第三军医大学第一附属医院呼吸内科

Department of Gastrointestial Surgery, Hebei General Hospital

The First Clinical College of Changzhi Medical College

Department of Gastrointestial Surgery, Heping Hospital Affiliated to Changzhi Medical College

AI问答

⁰